As the opioid crisis worsens, one Boston-based pharmaceutical company has used some impressive biology to create what it says amounts to a non-addictive, non-opioid painkiller.

As the New York Times reports, Vertex Pharmaceuticals seems to have shown some promising results in Phase 3 clinical trials, announced earlier this week in a statement, for patients who experienced “moderate-to-severe acute pain” after getting surgery.

Whereas opioids generally target both the brain and the body, which ultimately leads to their addictiveness, non-opioid drugs like Vertex’s VX-548 focus on peripheral nerves, or those outside of the brain and spine, the NYT explains. By blocking pain at the source, the logic goes, it can be averted before reaching the brain and developing the kind of feedback loop that lends itself to dependency.

Nerve cells in the brain demand an enormous amount of energy to survive and maintain their connections for communicating with other nerve cells. In Alzheimer’s disease, the ability to make energy is compromised, and the connections between nerve cells (called synapses) eventually come apart and wither, causing new memories to fade and fail.

A Scripps Research team, reporting in the journal Advanced Science, has now identified the energetic reactions in brain cells that malfunction and lead to neurodegeneration. By using a small molecule to address the malfunction, which occurred in the mitochondria—the cell’s major energy producers—the researchers showed that many neuron-to-neuron connections were successfully restored in nerve cell models derived from human Alzheimer’s patient stem cells. These findings highlight that improving mitochondrial metabolism could be a promising therapeutic target for Alzheimer’s and related disorders.

“We thought that if we could repair metabolic activity in the mitochondria, maybe we could salvage the energy production,” says senior author Stuart Lipton, MD, Ph.D., Step Family Foundation Endowed Professor and Co-Director of the Neurodegeneration New Medicines Center at Scripps Research, and a clinical neurologist in La Jolla, Calif. “In using human neurons derived from people with Alzheimer’s, protecting the energy levels was sufficient to rescue a large number of neuronal connections.”

Scientists at the University of Wisconsin–Madison (UWM) say they have created the first 3D-printed brain organoids that function like natural brain tissue.

“The neurons communicate, send signals, interact with each other through neurotransmitters, and even form proper networks with support cells that were added to the printed tissue,” said senior author Su-Chun Zhang.

The challenge: In the right conditions, stem cells will self-assemble into tiny, three-dimensional tissues that mimic features of the human brain. These “brain organoids” can be used to test drugs, study diseases, and more.